Dr. Rosenzweig Discusses the Standard of Care in Amyloidosis

Michael Rosenzweig, MD
Published: Tuesday, May 01, 2018



Michael Rosenzweig, MD, assistant professor in the Department of Hematology and Hematopoietic Cell Transplantation at City of Hope, discusses the standard of care for the treatment of patients with amyloidosis.

Autologous stem cell transplant, the current standard of care, is generally well tolerated by patients who are eligible, says Rosenzweig. For those who are not eligible, Rosenzweig says that a bortezomib (Velcade)-based regimen is often used, which is also generally well tolerated.

The treatment landscape of immunoglobulin light chain (AL) amyloidosis is rapidly expanding with novel systemic therapies such as daratumumab (Darzalex). Daratumumab is very well tolerated, and it is making its way to the frontline setting, says Rosenzweig. Clinical trials are underway exploring daratumumab in combination with bortezomib-based regimens for AL amyloidosis.


Michael Rosenzweig, MD, assistant professor in the Department of Hematology and Hematopoietic Cell Transplantation at City of Hope, discusses the standard of care for the treatment of patients with amyloidosis.

Autologous stem cell transplant, the current standard of care, is generally well tolerated by patients who are eligible, says Rosenzweig. For those who are not eligible, Rosenzweig says that a bortezomib (Velcade)-based regimen is often used, which is also generally well tolerated.

The treatment landscape of immunoglobulin light chain (AL) amyloidosis is rapidly expanding with novel systemic therapies such as daratumumab (Darzalex). Daratumumab is very well tolerated, and it is making its way to the frontline setting, says Rosenzweig. Clinical trials are underway exploring daratumumab in combination with bortezomib-based regimens for AL amyloidosis.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Emerging Treatment Options for Patients With High-Risk AMLMay 31, 20181.0
Oncology Briefings™: Updates in Pediatric Hepatic Veno-Occlusive Disease: Integrating Novel Therapeutic Strategies to Overcome Post-Transplant ObstaclesMay 31, 20181.0
Publication Bottom Border
Border Publication
x